Back to Trades
Murali Ramachandran
VP of Research and DevelopmentCIK 0001870016
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 1
- Buy transactions
- 0
- Sell transactions
- 0
- Companies
- 1
- Active
- 2025
Murali Ramachandran, VP of Research and Development, has filed 1 SEC report (2025), all concentrated in Kairos Pharma, LTD. (KAPA), totaling $0 in disclosed volume. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
1 loaded
| Nov 26 | KAPA Kairos Pharma, LTD. | Murali Ramachandran | VP of Research and Development | Grant | $0 |
1 filing